Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

French Proposals On Supply-Chain Security ‘Could Aggravate The Situation’

Local Industry Association Gemme Criticizes Shortage Measures In Planned Legislation

Executive Summary

Proposed French legislation that would address shortages by strengthening obligations to hold security stocks – with the threat of sanctions for suppliers – would be counter-productive, local generics industry association Gemme has warned.

You may also be interested in...



French Shortages Bill Would Impose ‘Dissuasive’ Penalties On Firms That Fail To Meet Tougher Obligations

The bill is the latest in a series of actions intended to address the continuing problem of medicine shortages.

France: Repatriating Drug Production Among Actions In ‘Roadmap’ For Tackling Shortages

The key themes of France’s latest initiative on shortages are repatriating the production of certain essential medicines and their active substances, earlier detection of potential supply problems, and more effective and transparent communications with all actors in the supply chain.

France’s Gemme Says Rebate Mechanism Puts Industry Future At Risk

French off-patent industry association Gemme has backed government suggestions that the country’s “safeguard clause” is in need of reforms and puts sustainable supply at risk, recommending that policymakers instead focus on boosting uptake – including through substitution for biosimilars and hybrids.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

GB153293

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel